LCID
Lucid Group, Inc.
LCID has a slight edge over THO overall, supported by stronger modeled upside and stronger fundamentals.
THO
Thor Industries, Inc.
THO has lower modeled downside risk, despite its lower overall score.
LCID Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
LCID's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
THO Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Stable | |
| Under pressure | |
| Healthy |
THO's balance sheet is currently healthy, and its profitability is stable, but its revenue and cash flow are under pressure.
LCID PE Valuation
LCID has no meaningful PE right now: it lost money over the past year.
THO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 5.6x | $18.83 | -76% |
| Fair | 19x | $63.46 | -18% |
| Forward | 20x | $77.29 | — |
| Expensive | 23x | $78.24 | +1.2% |
| Current | 23x | $77.29 | — |
Historical ranges are pointers, not guarantees.
THO's PE is in its expensive range at 23x. If earnings grow as analysts expect, today's price would be 20x next year's earnings, in its fair range.
LCID Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect LCID's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
THO Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for THO, with profitability holding steady. However, they disagree widely on these estimates.
LCID Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$13.08 | -$2.57 |
| Q2 2026 | -$13.65 | -$2.35 |
| Q1 2026 | -$13.15 | -$1.25 |
| Q4 2025 | -$12.09 | +$0.41 |
| Q3 2025 | -$10.51 | +$2.49 |
| Q2 2025 | -$11.30 | +$0.40 |
| Q1 2025 | -$11.90 | +$0.40 |
| Q4 2024 | -$12.50 | +$1.10 |
LCID is still losing money, but less than at its worst: $13.08 per share over the past year, against $16.50 at its worst in mid-2023.
THO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.92 | +16% |
| Q3 2026 | $3.38 | -30% |
| Q2 2026 | $4.96 | +19% |
| Q1 2026 | $5.63 | +49% |
| Q4 2025 | $5.28 | +35% |
| Q3 2025 | $4.84 | -2% |
| Q2 2025 | $4.18 | -15% |
| Q1 2025 | $3.78 | -25% |
| Q4 2024 | $3.92 | -28% |
THO has the edge over LCID on earnings quality, reporting a profit while its opponent remains loss making.
LCID Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $350.3M | +4.1% |
| Q2 2026 | $405.3M | +56% |
| Q1 2026 | $282.5M | +20% |
| Q4 2025 | $522.7M | +123% |
| Q3 2025 | $336.6M | +68% |
| Q2 2025 | $259.4M | +29% |
| Q1 2025 | $235M | +36% |
| Q4 2024 | $234.5M | +49% |
LCID has the edge over THO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -245% | +35 points |
| Q2 2026 | -267% | +43 points |
| Q1 2026 | -350% | -56 points |
| Q4 2025 | -204% | +109 points |
| Q3 2025 | -280% | +105 points |
| Q2 2025 | -310% | +83 points |
| Q1 2025 | -294% | +128 points |
| Q4 2024 | -313% | +156 points |
LCID's operating margin was −245% last quarter, up 35 points from the same quarter a year ago, near the top of its range since 2020.
THO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.3B | -8.4% |
| Q2 2026 | $2.8B | -3.9% |
| Q1 2026 | $2.1B | +5.3% |
| Q4 2025 | $2.4B | +11% |
| Q3 2025 | $2.5B | -0.4% |
| Q2 2025 | $2.9B | +3.3% |
| Q1 2025 | $2B | -8.6% |
| Q4 2024 | $2.1B | -14% |
THO's revenue fell from its 2022 peak and has held roughly level since: $2.3B last quarter, down 8.4% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 2.2% | -3.4 points |
| Q2 2026 | 4.8% | -0.6 points |
| Q1 2026 | 1% | +1.1 points |
| Q4 2025 | 1.4% | +1.4 points |
| Q3 2025 | 5.7% | +0.7 points |
| Q2 2025 | 5.4% | +0.3 points |
| Q1 2025 | -0.1% | -0.4 points |
| Q4 2024 | -0.1% | -2.9 points |
THO has the edge over LCID on profitability, with a higher operating margin.
LCID Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1B | -$84.2M |
| Q2 2026 | -$1.5B | -$463.2M |
| Q1 2026 | -$1.4B | -$849M |
| Q4 2025 | -$1.2B | -$417.1M |
| Q3 2025 | -$955.5M | -$333M |
| Q2 2025 | -$1B | -$271.6M |
| Q1 2025 | -$589.9M | +$125.1M |
| Q4 2024 | -$824.8M | -$77.6M |
LCID has burned cash in almost every quarter: −$5.2B over the past year, against −$3.4B the year before.
THO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $189.9M | -14% |
| Q2 2026 | $196M | -12% |
| Q1 2026 | -$145.2M | -2588% |
| Q4 2025 | -$74.8M | -1270% |
| Q3 2025 | $221.6M | -26% |
| Q2 2025 | $222.5M | -1.3% |
| Q1 2025 | $5.8M | +$146.1M |
| Q4 2024 | $6.4M | -67% |
THO has the edge over LCID on cash generation, producing positive trailing cash flow while its opponent burns cash.
LCID Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.3% | +12.5M shares |
| 1 year | +26% | +82.4M shares |
| 3 years | +73% | +166M shares |
LCID has 395M diluted shares, up 26% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | $2.2M |
| Q1 2020 | — |
THO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +163K shares |
| 1 year | -1.6% | -838K shares |
| 3 years | -2.4% | -1.3M shares |
| 5 years | -5.6% | -3.1M shares |
| Available history | -4.8% | -2.7M shares |
THO has the edge over LCID on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $34.3M |
| Q2 2026 | $50.5M |
| Q1 2026 | $25.2M |
| Q4 2025 | $5M |
| Q3 2025 | $50.9M |
| Q2 2025 | — |
| Q1 2025 | $1.7M |
| Q4 2024 | — |
THO spent $115M buying back its own shares over the past year, up 119% from the year before.
LCID Net Leverage
LCID's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
THO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.8x | Very low |
| Q2 2026 | 0.8x | Very low |
| Q1 2026 | 1.0x | Healthy |
| Q4 2025 | 0.7x | Very low |
| Q3 2025 | 0.6x | Very low |
| Q2 2025 | 0.9x | Very low |
| Q1 2025 | 1.2x | Healthy |
| Q4 2024 | 1.1x | Healthy |
THO's net debt is less than a year of its operating earnings (EBITDA).
LCID Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.9 | Neutral |
| Stochastic | 7.1 | Oversold |
LCID's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
THO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.9 | Neutral |
| Stochastic | 65.0 | Neutral |
THO's weekly RSI is 51 (neutral) and its Stochastic is 65 (neutral).
LCID PE vs Consumer Cyclical Sector
LCID has no meaningful PE right now: it lost money over the past year.
THO PE vs Consumer Cyclical Sector
| Metric | THO | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 18x | 27% above |
| PE % | 82 | 47 | 35 pts above |
THO is trading at 23x earnings, a 27% premium to the Consumer Cyclical sector's median of 18x.
LCID Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.53 | 7.9% below |
| 20 week MA | $4.88 | 33% below |
| 50 week MA | $7.33 | 56% below |
| 100 week MA | $15.4 | 79% below |
| 200 week MA | $31.9 | 90% below |
LCID is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
THO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $72.0 | 7.3% above |
| 20 week MA | $74.3 | 4% above |
| 50 week MA | $84.6 | 8.7% below |
| 100 week MA | $89.2 | 13% below |
| 200 week MA | $94.8 | 19% below |
THO has the edge over LCID on trend strength, trading above more of its moving averages.
LCID Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $98.9 | $100.4 | +1.5% |
| 2021 | $100.4 | $376.4 | +275% |
| 2022 | $376.4 | $67.0 | -82% |
| 2023 | $67.0 | $42.1 | -37% |
| 2024 | $42.1 | $32.0 | -24% |
| 2025 | $32.0 | $11.4 | -64% |
| 2026 YTD | $11.4 | $3.25 | -72% |
LCID has finished four years in a row lower, and it's down 72% so far in 2026.
THO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $74.4 | $102.4 | +38% |
| 2021 | $102.4 | $100.9 | -1.5% |
| 2022 | $100.9 | $77.3 | -23% |
| 2023 | $77.3 | $118.3 | +53% |
| 2024 | $118.3 | $95.4 | -19% |
| 2025 | $95.4 | $106.2 | +11% |
| 2026 YTD | $106.2 | $77.3 | -27% |
THO has the edge over LCID on returns for 2026, with the stronger performance.